Results: There were no group differences in prevailing adrenocorticotropic hormone (ACTH) or cortisol levels, but the association between ACTH and cortisol was moderated by METH + HIV+ group (β = −0.19, p < .05). Compared to METH-HIV− men, METH + HIV+ MSM displayed 10% higher log 10 cortisol levels per standard deviation lower ACTH. Both groups of methamphetamine-using MSM had lower insulin resistance and greater syndemic burden (i.e., sleep disturbance, severe depression, childhood trauma, and polysubstance use disorder) compared to METH-HIV− men. However, the disaggregated functional relationship between ACTH and cortisol in METH + HIV+ MSM was independent of these factors.
| INTRODUCTION
Although the acute effects of methamphetamine (meth) are attributable to sympathetic nervous system activation (Makisumi et al., 1998) , the hypothalamic-pituitary-adrenal (HPA) axis response is thought to play an important role in the reinforcing effects of stimulants (Goeders, 2002) . Consequently, meth has been shown to dysregulate HPA axis functioning in animal and human studies (Zuloaga, Jacobskind, & Raber, 2015) . Acute meth exposure increases plasma cortisol in humans (Harris, Reus, Wolkowitz, Mendelson, & Jones, 2003; Sachar et al., 1981) , and these meth-induced elevations in plasma cortisol may be partially independent of adrenocorticotropic hormone (ACTH) levels (Fehm, Holl, Steiner, Klein, & Voigt, 1984) . To date, the ACTH-independent mechanism(s) for the acute effects of meth on elevated cortisol have not been clearly elucidated.
Chronic meth use may exert direct effects and indirect effects via altered stress responses on HPA axis dysregulation. Chronic meth users display lower basal levels of cortisol (Carson et al., 2012) , which may be partially due to meth withdrawal. For example, increases in anxiety and depressive symptoms during meth withdrawal have been shown parallel elevations in serum ACTH and decreases in cortisol (Li et al., 2013; McGregor et al., 2005) . There is also some evidence that younger meth users have greater increases in salivary cortisol during the Trier Social Stress Task (King, Alicata, Cloak, & Chang, 2010) , but other research with stimulant users has not observed changes in salivary cortisol during this and another laboratory-based stressor (Harris, Reus, Wolkowitz, Mendelson, & Jones, 2005) . In one study examining a naturalistic stressor, meth-dependent men displayed increases in plasma cortisol 2 days after inguinal hernia surgery, but intercurrent meth use was not measured during this period (Pirnia, Givi, Roshan, Pirnia, & Soleimani, 2016) . More definitive research examining the mechanisms of HPA axis dysregulation in chronic meth users is clearly needed.
HPA axis dysregulation in chronic meth users is thought to be partially attributable to psychiatric comorbidities and metabolic changes.
There is increasing recognition that some groups of meth users such as meth-using men who have sex with men (MSM) experience a syndemic of co-occurring psychosocial health problems including depression, childhood trauma, and polysubstance use that fuel risk for HIV/AIDS (Carrico et al., 2012; Leserman, 2008; Lopez-Patton et al., 2016; Parsons, Grov, & Golub, 2012) . Syndemic factors such as depression could amplify HPA axis dysregulation among meth-using MSM. Although this is partially supported by laboratory-based research where depressed individuals display a paradoxical suppression of plasma cortisol in response to stimulants (Sachar et al., 1981) , other studies with chronic meth users have not observed associations of psychiatric symptoms with cortisol (King et al., 2010; Li et al., 2013) .
Finally, some animal research demonstrates that acute meth administration stimulates the pancreas to secrete insulin (McMahon, Andersen, Feldman, & Schanberg, 1971) , an effect that is augmented by a hyperthyroid state (McMahon, Feldman, & Schanberg, 1975) .
Although rising insulin levels lead to robust increases in plasma cortisol (Fehm et al., 1984) , in one prior study chronic meth users displayed a lower blood glucose and body mass index (BMI) compared to nonusers (Lv et al., 2016) . Taken together, syndemic burden and measures of glycemic metabolic functioning remain important possible confounders in examining HPA dysregulation among chronic meth users.
There are also well characterized neuroendocrine abnormalities in HIV (Brown, 2011) . One study of patients who died from AIDS documented adrenal compromise such that almost all pathology results (99%) displayed inflammatory infiltrates and approximately half (48%) had evidence of cytomegalovirus infection in the adrenal glands (Rodrigues et al., 2002) . HIV-associated dysregulation of the HPA axis is further supported by findings that HIV-positive men display elevated serum cortisol compared to HIV-negative men (Christeff, Gharakhanian, Thobie, Rozenbaum, & Nunez, 1992) . Although these studies were conducted prior to the era of highly active antiretroviral therapy (ART), there is increasing recognition that even those on contemporary ART regimens who achieve virologic suppression display persistent immune activation and inflammation (Lederman, Funderburg, Sekaly, Klatt, & Hunt, 2013 ) that could be both a cause and consequence of HPA dysregulation.
The overarching goal of the present study was to examine the potential implications of meth use alone and in combination with HIV for HPA axis dysregulation. Using an intact groups design, HIV-negative and HIV-positive meth-using MSM (METH + HIV− and METH + HIV+) were compared to HIV-negative, nonmeth-using men (METH-HIV−). Consistent with prior research on meth withdrawal (Li et al., 2013) , we hypothesized that there would be a main effect of meth such that both meth-using groups would display higher serum ACTH and lower serum cortisol (irrespective of HIV status). Because meth may increase cortisol through ACTH-independent pathways (Fehm et al., 1984) , we also hypothesized that the magnitude of the association between serum ACTH and serum cortisol would be lower in both meth-using groups (irrespective of HIV status). We also explored whether METH + HIV+ MSM displayed greater HPA axis dysregulation compared to METH + HIV− MSM. (First, Spitzer, Gibbon, & Williams, 1997) . All meth-using MSM were required to meet criteria for a DSM-IV meth use disorder. Participants also completed a battery of self-report psychosocial assessments and provided a fasting peripheral venous blood sample collected between 9 and 10 AM. Exclusion criteria, assessed via self-report, were a history of migraine, seizure, visual impairment, learning disorders, cardiovascular disease, diabetes mellitus, hypertension, current treatment for Hepatitis C or depression, and bereavement or loss of social support in the previous 3 months.
All METH + HIV− and METH + HIV+ MSM enrolled in this study met criteria for meth abuse or dependence. These groups of methusing MSM were compared to METH-HIV− men who were not required to identify as MSM. The comparison group of METH-HIV− men were not required to be MSM because we are aware of no evidence to support perturbations in baseal levels of HPA axis hormones (our primary outcome) in heterosexual men versus MSM. Of the 346 men enrolled, 37 (11%) were excluded because their blood glucose levels were greater than 110 mg/dl indicating that these were not fasting samples or the presence of prediabetes. There were no differences between the METH + HIV− (n = 6; 12%), METH + HIV+ (n = 20; 14%), and METH-HIV− (n = 11; 8%) groups in the proportion of participants excluded for a blood glucose greater than 110 mg/dl (χ 2 (2) = 2.93, p = .23). Among the 309 men who were included in the present study, 46 were METH + HIV− MSM, 127 were METH + HIV+ MSM, and 136 were METH-HIV− men. All participants were compensated $50 for their time and travel expenses.
| Measures 2.2.1 | Demographics and health status
Participants completed a demographic questionnaire assessing age, race/ethnicity, and health-related factors. All participants underwent a physical examination that included weight and height, which were used to calculate BMI.
| Syndemic conditions
Participants were administered the SCID and completed a battery of validated, self-report measures to screen for co-occurring sydnemic conditions. The Pittsburgh Sleep Quality index with a cutoff of >8 was administered to measure sleep disturbance (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989) . Depression was assessed using the 20-item Centers for the Epidemiologic Study of Depression, using a cutoff of >27 to indicate severe depression (Reisner et al., 2009 ).
Childhood trauma was assessed using a modified version of the Childhood Trauma Questionnaire, specifically the physical and sexual abuse subscales; a cutoff of >13 was used use for these subscales, representing severe to extreme childhood trauma (Bernstein et al., 2003) . Polysubstance abuse or dependence was assessed using the SCID (First et al., 1997) . A count variable was calculated to measure the presence of each of the four syndemic conditions (range = 0-4):
sleep disturbance, severe depression, severe childhood abuse, and a polysubstance use disorder.
| Insulin resistance, ACTH, and cortisol
All participants provided a fasting blood sample to assess glucose and insulin. Insulin resistance was calculated on the basis of glucose and insulin using the Homeostasis Model Assessment Insulin Resistance (HOMA-IR) formula (Matthews et al., 1985) , which has been reported to be superior in predicting cardiovascular risk relative to fasting glucose or fasting insulin alone (Gast, Tjeerdema, Stijnen, Smit, & Dekkers, 2012) . Serum ACTH (IBL America ELISA Cat# BM7023; ENZO ELISA Cat# ENZ-KIT 138-0001) and cortisol (IBL ELISA America Cat# BM79135; ENZO ELISA Cat# ADI-900-071) were assessed by means of a radioimmunoassay of 10 ml blood samples collected in EDTA tubes that were centrifuged at 3500 rpm for 15 min at 4°C. The collected specimen was then distributed in a microcentrifuge tube and stored at −20°F until processed.
| Statistical analyses
Analyses of variance and chi-square tests were utilized to examine METH/HIV group differences in demographic factors, BMI, HOMA-IR scores, serum ACTH levels, and serum cortisol levels. Post hoc probing of a significant analyses of variance F test was conducted with the Bonferroni correction to reduce the family-wise error rate. Because of their skewed distribution, HOMA-IR, ACTH, and cortisol values were log 10 transformed. The count of syndemic conditions violated the homogeneity of variance assumption, and as a result a chi-square test was used to examine METH group differences in the proportion of participants screening positive for three or more syndemic conditions.
Subsequently, a multiple linear regression analysis tested whether the METH/HIV groups moderated the association of ACTH and cortisol after controlling for age, race/ethnicity, BMI, HOMA-IR score, and number of syndemic conditions. The interactions of the METH + HIV − and METH + HIV+ groups with ACTH were entered into a separate regression block and only significant interaction terms were retained in the final model. The significance of the incremental increase in explained variance (Δ R 2 ) in log 10 cortisol was tested to confirm moderation by the METH/HIV groups. The unadjusted parameter estimates for significant correlates were transformed using a simple formula (100*[10 B
-1]) to characterize the percent change in log 10 cortisol per unit change in the independent variables that were statistically significant.
| RESULTS
Participant age ranged from 18 to 55 years, with a mean of 36.8
(SD = 9.8). Half of participants were Hispanic/Latino (51%), 26% were African American, 19% were Caucasian, and 4% were other racial or ethnic minorities or multiracial. Approximately half (47%) had a monthly personal income of less than USD $500. Most participants (61%) had a BMI indicating they were overweight or obese. Among the meth-using groups, one-third (37%) met criteria for meth abuse and approximately two-thirds met criteria for meth dependence (63%). Approximately 70% of meth-using participants met criteria for a polysubstance use disorder. The majority of METH + HIV+ participants (88%) were currently prescribed ART.
As detailed in Table 1, for HPA dysregulation, we were unable to examine the association of HIV alone without a METH-HIV+ group in this study. There is increasing recognition of persistent inflammation in treated HIV infection (Lederman et al., 2013) , which is thought to be due in part to intestinal damage by HIV and could be augmented by alcohol or other substance use (Justice & Falutz, 2014) . HIV-induced increases in pro-inflammatory cytokines such as IL-6 could bind to adrenal inflammatory receptors and amplify cortisol output independent of prevailing ACTH levels (Path et al., 1997) . It is also plausible that HIV-associated adrenal (Carrico et al., 2012; Lopez-Patton et al., 2016; Parsons et al., 2012) .
Despite the fact that greater syndemic burden was not associated with higher cortisol, the implications of syndemic conditions for HPA axis functioning remains an important area for further research with MSM.
Results of the present study should be interpreted in context of some important limitations. First, serum measures cannot capture important aspects of diurnal variation in HPA axis functioning. Future research should include repeated measures of salivary cortisol to better understand whether meth users display dysregulation of diurnal cortisol patterns. Salivary and urinary specimen collection methods should also be employed to examine meth-related changes in output of sympathetic-adrenal-medulla (SAM) axis hormones such as norepinephrine. The SAM axis may be more responsive to meth-induced changes being that its acute effects are mediated by the sympathetic nervous system and increases in norepinephrine could modulate HPA axis functioning (Dinan & Cryan, 2012) . It is also noteworthy that this study examined basal levels of ACTH and cortisol. Future studies should consider including functional measures of positive (e.g., ACTH challenge) and negative (e.g., dexamethasone suppression) feedback to better understand the underlying source(s) of HPA dysregulation.
Studies should also examine dose-response associations of meth use with HPA axis dysregulation by administering self-report measures as well as collecting specimens (e.g., urine and hair) for toxicology testing.
Finally, another possible limitation of this study is that both meth-using MSM groups were compared to METH-HIV− men who were not required to be MSM. Although findings remained significant after controlling for group differences in syndemic burden, future research should examine whether results generalize to meth-using heterosexual men.
| CONCLUSIONS
This study demonstrates that HIV-positive, meth-using MSM display disaggregation of the functional relationship between ACTH and cortisol compared to HIV-negative, non-meth-using men. These findings will inform the scientific premise for future research examining the bio-behavioral processes whereby HIV alone or in combination with meth contribute to HPA axis dysregulation in MSM. Further research should examine the extent to which HIV alone or in combination with meth potentiate microbial translocation and inflammatory processes that could account for greater HPA axis dysregulation. 
